From October 08 to 10, 2024, the 33rd CPhI Worldwide 2024 was held grandly at the Milan Convention Center in Italy. As the largest global event in the pharmaceutical raw material industry, CPhI Worldwide has become a pivotal communication hub in the international pharmaceutical community since its inception. It provides participants with an unparalleled platform to showcase the latest products, technologies, and share industry insights, earning the title of the "Heart of the Pharmaceutical Industry". This year's exhibition attracted over 62,000 pharmaceutical company owners, raw material suppliers, research institutions, and industry experts from more than 166 countries and regions, with more than 2400 exhibitors participating.

Grand Shuyang Life Sciences (Chengdu) Co., Ltd. (hereinafter referred to as "Grand Shuyang"), a leading enterprise in China's plasma-derived products sector, has consistently participated in CPhI Europe over the years. Grand Shuyang's plasma-derived products are not only highly regarded in the Asia-Pacific, Eastern Europe, and South American markets, but they also rank among the top in China's export business. This exhibition aims to enhance international market sales and access to Grand Shuyang's products, provide business value to partners, and introduce more competitive offerings to the global market.

During the exhibition, Grand Shuyang's booth attracted significant attention. The company engaged in extensive discussions with industry experts, global distributors, and clients, exploring opportunities for new product registration, market entry, and commercialization. These interactions not only deepened clients' trust in Grand Shuyang's technical expertise and service quality but also reinforced the company's leadership position within the industry.

Simultaneously, Zhou Hui, President of the China Chamber of Commerce for Import & Export of Medicines & Health Products, and Geng Xiewei, Commercial Counselor of the Chinese Consulate General in Milan, visited for an inspection and research tour, providing high praise and support to the Grand Shuyang team.

Looking ahead, Grand Shuyang will continue to prioritize patient needs, focusing on plasma-derived products while leveraging collaboration in biomedicine as a key driver of development. The company will persistently enrich its product pipeline, actively explore international markets, and accelerate brand enhancement. It aims to become an "international high-quality service provider across the entire plasma-derived product chain", delivering superior quality products and exceptional services to patients, thereby making significant contributions to the advancement of human health.